Product Description

Dual GLP-1/GIP Receptor Agonist

Tirzepatide (20mg) is supplied in Australia by Daza Enhanced with fast domestic shipping to all states and territories.

Tirzepatide is a dual incretin agonist that activates both GLP-1 and GIP receptors. Where semaglutide (Ozempic/Wegovy) acts on GLP-1 alone, Tirzepatide’s dual activity is associated with stronger outcomes in clinical research: Phase 3 SURMOUNT trials reported mean body weight reductions of up to 22.5% over 72 weeks — one of the largest figures documented in weight-management research. Tirzepatide established the dual-agonist benchmark now used to evaluate newer tri-agonist compounds like Retatrutide.

Mechanism of research interest: GLP-1 activation modulates appetite and gastric emptying; GIP activation modulates insulin sensitivity and fat metabolism. The combined signal is studied for appetite reduction, glycaemic control, and preferential fat-mass reduction.

Key Research Areas

• Fat Loss Research — Up to 22.5% body weight reduction over 72 weeks in Phase 3 trials
• Appetite Regulation — Studied for reduced food intake via gastric emptying and central appetite signalling
• Glycaemic Control — Studied for insulin sensitivity and HbA1c reduction in type 2 diabetes research
• Body Composition — Studied for preferential fat-mass reduction over lean mass
• Cardiometabolic Markers — Studied for blood pressure, cholesterol, and cardiovascular risk improvements
• Hepatic Steatosis — Emerging research on fatty liver markers and NASH-related models

Supplied as lyophilized powder, verified by HPLC and mass spectrometry. 20mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.